Clinical review report: Travoprost 0.003% (Izba) (Novartis Pharmaceuticals Canada Inc. on behalf of Icon Canada Inc.)
The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of travoprost 0.003% PQ for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma(OAG)
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
September 2017, 2017
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of travoprost 0.003% PQ for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma(OAG) |
|---|---|
| Item Description: | "Version: Final." |
| Physical Description: | 1 PDF file (48 pages) illustrations |